Saroglitazar 2 mg (N = 380) | Saroglitazar 4 mg (N = 386) | Pioglitazone 30 mg (N = 389) | |
---|---|---|---|
Subjects characteristics | |||
Age (years), m ± SD | 51.90 ± 10.38 | 51.34 ± 10.06 | 51.84 ± 9.76 |
Female, n (%) | 164 (43.16%) | 143 (37.05%) | 167 (42.93%) |
Male, n (%) | 216 (56.84%) | 243 (62.95%) | 222 (57.07%) |
Weight (kg), m ± SD | 70.27 ± 11.84 | 69.09 ± 11.46 | 69.49 ± 11.59 |
BMI (kg/m2), m ± SD | 26.48 ± 4.03 | 25.94 ± 3.87 | 26.33 ± 4.07 |
Glycemic parametersa, m ± SD | |||
HbA1C (%) | 9.76 ± 1.59 | 9.72 ± 1.58 | 9.49 ± 1.54 |
FPG (mg/dL) | 166.08 ± 46.14 | 165.41 ± 51.39 | 165.08 ± 51.45 |
PPG (mg/dL) | 275.90 ± 84.74 | 277.42 ± 90.57 | 277.35 ± 88.05 |
Lipid parametersa, m ± SD | |||
TG (mg/dL) | 163.87 ± 91.49 | 172.52 ± 123.67 | 166.20 ± 89.93 |
LDL-C (mg/dL) | 117.11 ± 36.92 | 112.93 ± 34.89 | 116.77 ± 32.31 |
VLDL-C (mg/dL) | 32.77 ± 18.30 | 34.50 ± 24.73 | 33.24 ± 17.99 |
HDL-C (mg/dL) | 42.39 ± 10.58 | 41.50 ± 10.47 | 42.64 ± 12.72 |
TC (mg/dL) | 176.98 ± 42.67 | 174.03 ± 39.32 | 176.42 ± 37.83 |
Non HDL-C (mg/dL) | 134.62 ± 41.06 | 132.54 ± 39.12 | 133.78 ± 35.39 |
Apolipoproteinsa, m ± SD | |||
Apo A1 (mg/dL) | 128.72 ± 23.87 | 124.89 ± 23.05 | 127.15 ± 22.80 |
Apo B (mg/dL) | 100.64 ± 29.77 | 98.79 ± 26.06 | 100.60 ± 23.07 |